본문으로 건너뛰기
← 뒤로

Recurrent Myocarditis After COVID Vaccination in a Patient With FLNC Mutation Undergoing Treatment for Lymphoma.

JACC. Case reports 2026 Vol.31(7) p. 106506

Singh S, Campbell LC, Okwuosa IS, Wilsbacher LD, Cremer PC, Knight BP, Gordon LI, Akhter N

📝 환자 설명용 한 줄

[BACKGROUND] Filamin C (FLNC) variants are often associated with structural cardiomyopathies but rarely myocarditis.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Singh S, Campbell LC, et al. (2026). Recurrent Myocarditis After COVID Vaccination in a Patient With FLNC Mutation Undergoing Treatment for Lymphoma.. JACC. Case reports, 31(7), 106506. https://doi.org/10.1016/j.jaccas.2025.106506
MLA Singh S, et al.. "Recurrent Myocarditis After COVID Vaccination in a Patient With FLNC Mutation Undergoing Treatment for Lymphoma.." JACC. Case reports, vol. 31, no. 7, 2026, pp. 106506.
PMID 41532901

Abstract

[BACKGROUND] Filamin C (FLNC) variants are often associated with structural cardiomyopathies but rarely myocarditis.

[CASE SUMMARY] A 60-year-old man with newly diagnosed B-cell lymphoma and initiation of cancer therapy presented with substernal chest pain. He had experienced myocarditis 2 years ago from a COVID-19 vaccine or possible infection; however, he received another COVID-19 booster in anticipation of upcoming cancer therapy. He was diagnosed with acute myocarditis, and his course was complicated by cardiac arrest requiring multidisciplinary management. Outpatient genetic testing revealed a pathogenic FLNC variant.

[DISCUSSION] This report highlights the case of a patient with FLNC mutation who developed recurrent myocarditis in the setting of exogenous factors, including the COVID-19 vaccine and a history of lymphoma and immunotherapy.

[TAKE-HOME MESSAGES] Myocarditis may be the initial presentation for certain genetic cardiomyopathies. Genetic testing should be strongly considered in patients with multiple episodes of myocarditis.

같은 제1저자의 인용 많은 논문 (5)